**Core Concept**
Curanium drugs, also known as non-depolarizing neuromuscular blocking agents, are a class of muscle relaxants that competitively block the action of acetylcholine at the nicotinic receptors on the neuromuscular junction, thereby preventing muscle contraction.

**Why the Correct Answer is Right**
The Curanium drugs, including drugs like Pancuronium and Vecuronium, bind to the nicotinic receptors on the muscle endplate, competing with acetylcholine for receptor sites. This competitive inhibition reduces the binding of acetylcholine to the receptor, leading to a decrease in the release of calcium ions from the sarcoplasmic reticulum and ultimately resulting in muscle relaxation. The Curanium drugs do not depolarize the muscle membrane, unlike depolarizing neuromuscular blockers like Succinylcholine.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because it does not accurately describe the mechanism of action of Curanium drugs, which is competitive inhibition of acetylcholine at the nicotinic receptor.
* **Option B:** This option is incorrect because it describes the mechanism of action of depolarizing neuromuscular blockers, not Curanium drugs.
* **Option C:** This option is incorrect because it is not a known mechanism of action for any muscle relaxant class, including Curanium drugs.

**Clinical Pearl / High-Yield Fact**
It's essential to remember that Curanium drugs have a longer duration of action compared to depolarizing neuromuscular blockers and should be used with caution in patients with renal or hepatic impairment.

**Correct Answer: D. Competitive inhibition of acetylcholine at the nicotinic receptor.**